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Summary Clofibrate (CPIB) is a drug applied as an antilipidaemic agent in mammals. In this work we have
tested its efficacy in vivo on the growth kinetics of P 1798(sc) lymphoma transplanted to recipient
(BALB/c x AKR)F1 mice. Our results show a facilitation of the tumour growth rate in treated recipients. This
fact may be related to an effect of the agent on the recipient which produces a decrease in the immune
response as was confirmed on testing CPIB on thymus-dependent antigens in haemolytic plaque assays.
Immune responses to experimental tumours can
either facilitate their growth or cause their
eradication from the host. Furthermore, several
reports have indicated that the resistance of tumour
cells to humoral immune attack is directly
correlated with their ability to synthesize complex
lipids as measured by the incorporation of fatty
acids into extractable lipid macromolecules
(Schlager & Ohanian, 1977). Some of these cells can
be rendered susceptible to immune attack by
treatment with certain metabolic inhibitors and
chemotherapeutic drugs used in cancer treatment.
Clofibrate (ethyl-p-chlorophenoxyisobutyrate
(CPIB)), which has been used as an antilipidaemic
agent in mammals (Thorp & Waring, 1962), was
used to test the susceptibility of guinea-pig
hepatomas to killing by antibody and complement;
the results obtained showed an increased killing in
vitro, and this effect was reversible when the cells
were cultured in the absence of the drug (Schlager
& Ohanian, 1977; Schlager et al., 1978). This
phenomenon was explained by the involvement of
particular lipid moieties and the ability to
synthesize lipids in resistance to killing of these
tumour cells by antibody and complement.
We have tested the effects of CPIB on the growth
kinetics of the P 1798(sc) lymphoma in
(BALB/c xAKR)F1 mice (BAF1). Furthermore,
changes induced by this drug in the immune
response to thymus-dependent antigens in BAFI
mice have been evaluated.
Materials and methods
Mice
BALB/c and AKR mice were purchased from
Bomholtgard (Denmark) and crossed in our animal
facilities to generate (BALB/c x AKR)Fl (BAF1)
hybrids. BALB/c and CBA/N mice were obtained
from OLAC (England) and crossed to obtain
(BALB/c x CBA/N)F1 (BNFl) hybrids.
Tumours
P 1798(sc) lymphoma is a variant obtained in our
laboratory (Ubeira, 1982) from the oestrogen-
induced P 1798 T-cell lymphoma (Lampkin &
Potter, 1958). This subline was characterized by a
greater survival capacity in recipient mice than
the original P 1798 tumour.
Drugs
Clofibrate (ethyl-p-chlorophenoxyisobutirate
(CPIB)) (ICI-Farma, Spain) was used in doses of
500mgkg-1 in BAFI mice and doses of
500mgkg-' and 250mgkg-' in BNFI mice. In all
cases was injected daily i.p. The CPIB-LD50 is
1965mgkg-1 i.p. in mice (S. Mufioz, Personal
communication).
Determination ofthe growth kinetics ofP1798(sc)
tumour
BAF1 mice, 6-8 weeks old, were injected s.c. with
107 cells of the ascitic form of the P 1798(sc)
tumour. Cells were washed x 3 in Hank's Balanced
Salt Solution (HBSS) prior to inoculation. Viability
was determined by the Trypan Blue exclusion
method (Mishell & Shiigi, 1980). Treatment with
CPIB at the doses indicated above was initiated at
the same time as tumour inoculation; controls were
injected with an equal volume of HBSS.
From Day 5 after inoculation until death, tumour
growth was measured using a gauge. Tumour
volume was calculated as V =D x d2 x 0.4, where D
and d were the diameters measured. Attia et al.
(1965).
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Extraction oftumour lipids and thin layer
chromatography
P 1798(sc) cells were obtained from groups of 3
tumour-bearing mice, CPIB-treated or untreated, as
described above. The cells were processed using a
wire-screen and nylon cheese-cloth and washed in
HBSS following the usual procedure. Finally, cells
were centrifuged at 3000g for 15min and the wet
weight was determined.
Lipids were extracted by the method of Folch et
al. 1957 using chloroform-methanol (2: 1). They
were concentrated in a rotavapor-R (Buchi) at 60°C
in N2 atmosphere and redissolved in chloroform to
a final concentration of 5-10mgml-1.
One-dimensional chromatography was carried
out in 0.0025 x 20 x 20cm Merck plates using a
mixture of chloroform-methanol-water (65:25:4) as
solvent system (Skipski & Barclay, 1969). TLC
plates were developed in an iodine vapour chamber.
Determination oftriglycerides and cholesterol
Cholesterol and triglycerides were determined
following the methods by Allain et al. (1974) and
Bucolo & David (1973).
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Effect ofCPIB on the immune response
To determine the effect of CPIB on the immune
response untreated BAFI and BNF1 mice and mice
treated with the CPIB doses previously described
were used. Immunization was carried out on the
third day of CPIB treatment: (a) BAFI mice
received 108 sheep red blood cells (SRBC) i.p. and
(b) BNF1 mice received 200pg of phosphoryl-
choline-Keyhole Limpet Haemocyacin (PC-KLH)
i.v. as described previously (Quan et al., 1981). The
response was evaluated using the haemolytic plaque
assay (Cunningham & Szemberg, 1968), using
SRBC in experiment (a) and PC-SRBC in
experiment (b).
Results
Effect ofCPIB on P 1798(sc) growth kinetics
Untreated BAFI mice and mice treated with CPIB,
were injected with P 1798(sc) lymphoma cells; from
the 5th day after inoculation, tumour diameters
were measured until death. P 1798(sc) growth
kinetics are presented in Figure 1. Transplanted
Time (d) after inoculation
Figure 1 P 1798(sc) growth kinetics in CPIB-treated (0) and untreated (0) BAFI mice. Each point is the
mean of tumour volume +s.d. Initial groups were of 5 mice. The measurements were made while 2 mice
remained alive.
Tumour volume was calculated as explained in text.CLOFIBRATE: IMMUNOSUPPRESSION AND TUMOUR GROWTH
BAFI mice treated with CPIB showed an
accelerated progression when compared with
untreated tumour recipients. Beyond the 8th day,
different rates of progression were observed and
survival of treated mice was also affected (Figure
2). Controls exhibited a partial regression between
days 10 and 16. Death of mice occurred-when the
primary tumour volume was between 1.2-
1.4 x 03mm-3 in both instances.
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Figure 2 Survival curves for groups of 5 P 1798(sc)
tumour-bearing untreated ( ) and CPIB-treated
mice (----).
Effect ofCPIB on lipidplasma contents
CPIB treatment also altered the plasma triglyceride
and cholesterol content (Table I). We also observed
changes in electrophoretic mobility of plasma
lipoproteins in CPIB-treated mice compared with
untreated mice (data not shown). Nevertheless, the
lipid content of the tumour cells at the doses of
CPIB used did not reveal any differences (Figure 3);
only minimal quantitative differences were detected
in the treated and untreated tumour samples.
Table I Triglyceride and plasma cholesterol contents of
CPIB-treated and control mice.
Treated Untreated
Triglycerides 33+7 234+29
Cholesterol 67+5 91+ 8
Each value represents the mean of 5 mice +s.d.
expressed in mg 100 1 ml.
Paradoxically, the cholesterol level appeared with
an increment in tumour cells of CPIB treated mice.
Effect of CPIB on the SRBC and PC-KLH PFC-
responses
In an attempt to demonstrate the involvement of
the immune system in the facilitation of tumour
growth after CPIB treatment, the haemolytic
plaque assay was used to measure the response of
(CEPI)
CEP2
CEP3
CEP4
(LECI)
LEC2
R.Le Y_ wX 2'Y#: iEC':3:2 .....................
(0)
MSL UTC CPIB
Figure 3 Thin layer chromatogram of P1798(sc) lipid
extract from CPIB treated (CPIB) and untreated
control (UTC) mice and an artificial mixture of
standard lipids (MSL).
TG: Triglycerides (Tripalmitin and Triolein, Sigma
Chemical Co. (99% pure)), CHOL. Cholesterol, Fluka
AG. (99% pure); FFA: Free fatty acids (Linoleic acid
grade III, Sigma Chemical Co. (99% pure)); CEP 1: L-
fl-y-Dihexadecyl-a-cephalin, Fluka AG. (Grade puriss);
CEP 2: L-fi-y-Dipalmitoyl-ax-cephalin, Fluka AG. (99%
pure); CEP 3: L-fi-y-Dimyristoyl-a-cephalin, Fluka
AG. (99% pure); CEP 4: N, N'-Dimethyl-L-cephalin,
Dipalmitoyl, Sigma Chemical Co. (98% pure); L LEC
1: L-fi-y-Dilauroyl-a-lecithin Fluka AG. (99% pure);
LEC 2: L-a-Phosphatidyl choline, Distearoyl Sigmna
Chemical Co. (98% pure); LEC 3: L-fi-y-Dihexade-cyl-
a-lecithin Fluka AG. 0: Origin. SF: Solvent front.
BAFI mice to a particulate thymus-dependent
antigen (SRBC). Also the response to phosphoryl-
choline (PC) determinants using PC-KLH as
antigen was tested (Table II). Using SRBC as
antigen and CPIB doses of 500mgkg'I in BAFi
mice, the PFC-response was -25% of the control
response. A depression was also detected in BNFI
mice using PC-KLH as antigen, at 2 doses of CPIB
(500 and 250mgkg- l In this last experiment, the
PFC-response of the treated mice was - 507% of
that, of the controls. Responses with the two CPIB
doses tested showed no significant differences
(P<O0.6).
(SF)
TG
CHOL
FFA
419420 F.M. UBEIRA et al.
Table II Effect of CPIB treatment on the PFC response
to two thymus-dependent antigens.
PFCper 106
Animalsc Antigen CPIB Dose cells+s.d.
BAF1(Control) SRBC 1045+ 128k
BAF1 SRBC 500mgkg-1 260+41
BNF1(Control) PC-KLH 1418 +223b
BNF1 PC-KLH 250mgkg-' 700+76
BNF1 PC-KLH 500mgkg-1 635+73
'PFC response measured against SRBC (P<0.005).
bPFC response measured against PC coupled SRBC
(P<0.05).
CFour mice were used for each determination.
Discussion
Several reports have been published associating
lipids with tumour susceptibility to immune attacks.
Some of them have demonstrated an effect of CPIB
on the incorporation of certain metabolites in vitro
which parallels an increased susceptibility of
tumour cells to lysis with antibodies plus
complement.
The biochemical mechanism of the effects of
CPIB on lipid metabolism is not fully understood;
it seems that CPIB alters the systems engaged in the
transformation occurring in lipoproteins and the
hepatic synthesis ofcholesterol (Avoy et al., 1954).
We studied the CPIB effect on tumour growth
kinetics in mice. Our model was the murine
P 1798(sc) lymphoma which is a variant able to
develop tumours in BALB/c mice and C57BL/6 and
CBA/Ca mice strains treated with Pristane
(2,6,10,14-tetramethyl pentadecane).
Our first objective was to select the appropriate
dose. CPIB has a half life of 12h due to the effect
of serum esterases which degrade the molecule to p-
chlorophenoxyisobutyric acid, a compound easily
inactivated by hepatic glucuronidation (Korolkovas
& Burckhalter, 1978). CPIB is being used
extensively in the treatment of atherosclerosis. Few
toxic effects result from regular doses in man (20-
30mgkg-') or large amounts in animals. [Only one
case has been reported on the effect of large
quantities in man (Greenhouse, 1968); a 15-year-old
boy took 49 capsules of CPIB and remained
asymptomatic during the entire period of
observation]. The 2 doses used in this work were 4
and 8 times smaller that the mouse LD50
(1965mgkg-1 i.p.) and 20 and 10 times greater
than the human therapeutic dose, respectively. Even
at this high dose, CPIB did not diminish tumour
growth rate; in fact, an increase in tumour growth
kinetics in BAFI recipients was observed. In order
to explain these findings, the effect of CPIB on
treated recipients was first tested. There was a
reduction in triglycerides and serum cholesterol
levels, especially affecting the former, and also
alterations in serum lipoprotein electrophoretic
mobility, as reported by others (Bowman & Rand,
1980).
Once antilipidaemic activity was demonstrated
the effect of CPIB on the lipid composition of
tumour cells in vivo was determined.
Chromatographic patterns of tumour cell lipid
extracts were found to be similar in both CPIB-
treated and untreated P 1798(sc) recipients. These
results showed that the effect on the lipid
component of the tumour cells was marginal under
these conditions.
One possible explanation of the increased
P 1798(sc) growth-rate in CPIB-treated mice could
thus be the involvement of the immune system.
P 1798(sc) is a tumour which originally arose in
BALB/c mice and able to surmount histocompati-
bility barriers in some instances (Ubeira, 1982). On
the other hand, BAF1 mice are able to mount some
immune reactivity against the P 1798(sc) tumour.
The immunization of BAF1 mice with P 1798(sc)
cells may confer transplantation resistance to the
same tumour. Furthermore, sera from immunized
BAFI mice exhibit cytotoxicity against P 1798(sc)
cells. Selective absorption of BAF1 anti-P 1798(sc)
sera has shown that a minimum of two antigens
areinvolvedinresponseofBAFl miceagainstP1798(sc)
tumour (data not shown). These two antigens could
elicit a response capable of retarding tumour
growth, but P 1798(sc) can overcome this reactivity
throughout unknown mechanisms. This explanation
is in agreement with the partial tumour regression
observed in control but not in treated (immuno-
depressed) mice between days 10 and 16 following
inoculation.
The haemolytic plaque assay was employed to
evaluate the effect of CPIB on the immune
response. The PFC results for two models of the
thymus-dependent response-one complex, to
SRBC in CPIB-treated BAFI mice, and the other,
more defined to PC, using PC-KLH as antigen in
CPIB-treated BNF1 mice-showed a significantly
decreased response in both instances. This favours
the hypothesis of a facilitating role for CPIB in
increasing the tumour growth rate in treated
recipients associated by immunological impairment.
Antitumour immune mechanisms are complex
and not well understood. In this work only the
antibody synthesizing ability of the host was
studied to explain the facilitation of P 1798(sc)
growth. Reports of increased sensitivity of CPIB-
treated tumour cells to lysis in vitro by antibodies
plus complement (Schlager & Ohanian, 1977) were
responsible for this approach. However, despite theCLOFIBRATE: IMMUNOSUPPRESSION AND TUMOUR GROWTH 421
large doses used, this effect could be observed in
vivo. It is possible that CPIB may also affect the
cell-mediated immunity in the host. Experiments to
clarify the effect of CPIB on the cellular immune
response are being carried out.
The effect of CPIB is different in rodents and
humans. Thus, hepatomegaly, proliferation of
smooth endoplasmic reticulum and large increases
in the number of hepatic peroxisomes induced by
clofibrate in rodents could not be demonstrated in
man (Cohen & Grasso, 1981). Similarly CPIB can
act differently on the immune system of rodents
and humans. Although a reduction of plasma
protein components, including IgM, IgG and IgA,
in patients treated with CPIB has been reported
(Cederblad & Korsan-Bengtsen, 1976), further
studies are needed to definitively establish the
effects of CPIB on the human immune system.
Clofibrate is a drug with inconclusive or
conflicting evidence of carcinogenicity in relation to
hepatic, pancreatic and gastrointestinal
malignancies (Hoover & Fraumeni, 1981; Reddy &
Qureshi, 1979; Cohen & Grasso, 1981). The hepatic
peroxisome proliferation effect is related to
carcinogenicity in rats (Reddy & Krishnakantha,
1975), However, results reported here are consistent
with the possibility that CPIB-induced tumour
facilitation in rodents is not so much a function of
if carcinogenic/tumour promotional activity as of
its properties as an immunological depressant.
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